- Home
- FHI vs ACAD Comparison
FHI vs ACAD Comparison
Compare FHI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- ACAD
- Stock Information
- Founded
- FHI 1955
- ACAD 1993
- Country
- FHI United States
- ACAD United States
- Employees
- FHI N/A
- ACAD N/A
- Industry
- FHI Investment Managers
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- FHI Finance
- ACAD Health Care
- Exchange
- FHI Nasdaq
- ACAD Nasdaq
- Market Cap
- FHI 4.0B
- ACAD 3.5B
- IPO Year
- FHI N/A
- ACAD 2004
- Fundamental
- Price
- FHI $48.39
- ACAD $22.00
- Analyst Decision
- FHI Buy
- ACAD Buy
- Analyst Count
- FHI 7
- ACAD 21
- Target Price
- FHI $47.86
- ACAD $29.43
- AVG Volume (30 Days)
- FHI 465.5K
- ACAD 2.0M
- Earning Date
- FHI 10-30-2025
- ACAD 11-05-2025
- Dividend Yield
- FHI 2.82%
- ACAD N/A
- EPS Growth
- FHI 53.50
- ACAD 615.00
- EPS
- FHI 4.52
- ACAD 1.33
- Revenue
- FHI $1,681,523,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- FHI $7.41
- ACAD $14.01
- Revenue Next Year
- FHI $4.73
- ACAD $12.00
- P/E Ratio
- FHI $10.66
- ACAD $16.61
- Revenue Growth
- FHI 5.55
- ACAD 14.41
- 52 Week Low
- FHI $35.05
- ACAD $13.40
- 52 Week High
- FHI $54.42
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- FHI 30.81
- ACAD 51.82
- Support Level
- FHI $50.69
- ACAD $20.33
- Resistance Level
- FHI $52.09
- ACAD $22.10
- Average True Range (ATR)
- FHI 1.23
- ACAD 0.81
- MACD
- FHI -0.32
- ACAD 0.23
- Stochastic Oscillator
- FHI 2.50
- ACAD 92.40
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.